Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.47 USD
-0.17 (-4.67%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.46 -0.01 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVIR 3.47 -0.17(-4.67%)
Will AVIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVIR
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Other News for AVIR
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update ...
Atea Pharmaceuticals (AVIR) Launches Phase 3 Trial for Hepatitis C Treatment | AVIR Stock News
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing ...
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial